Advertisement

Inflammation

, Volume 12, Issue 4, pp 361–371 | Cite as

Analgesic and antiinflammatory activity of constituents ofCannabis sativa L.

  • E. A. Formukong
  • A. T. Evans
  • F. J. Evans
Original Articles

Abstract

Two extacts ofCannabis sativa herb, one being cannabinoid-free (ethanol) and the other containing the cannabinoids (petroleum), were shown to inhibit PBQ-induced writhing in mouse when given orally and also to antagonize tetradecanoyl-phorbol acetate (TPA) -induced erythema of mouse skin when applied topically. With the exception of cannabinol (CBN) and δ1-tetrahydrocannabinol (δ1-THC), the cannabinoids and olivetol (their biosynthetic precursor) demonstrated activity in the PBQ test exhibiting their maximal effect at doses of about 100Μg/kg. δ1-THC only became maximally effective in doses of 10 mg/kg. This higher dose corresponded to that which induced catalepsy and is indicative of a central action. CBN demonstrated little activity and even at doses in excess of 10 mg/kg could only produce a 40% inhibition of PBQ-induced writhing. Cannabidiol (CBD) was the most effective of the cannabinoids at doses of 100Μg/kg. Doses of cannabinoids that were effective in the analgesic test orally were used topically to antagonize TPA-induced erythema of skin. The fact that δ1-THC and CBN were the least effective in this test suggests a structural relationship between analgesic activity and antiin-flammatory activity among the cannabinoids related to their peripheral actions and separate from the central effects of δ1-THC.

Keywords

Public Health Acetate Internal Medicine Central Action Central Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pars, H. G., R. J.Razdan, and J. F.Howes. 1977. Potential therapeutic agents derived from the cannabinoid nucleus.Adv. Drug Res. 11.Google Scholar
  2. 2.
    O. L. Davies, J. Raventos, andA. L. Walpole. 1946. A method for evaluation of analgesic activity using rats.Br. J. Pharmacol. 1:255–264.Google Scholar
  3. 3.
    Gill, E. W., W. D. M. Paton, andR. G. Pertwee. 1970. Preliminary experiments on the chemistry and pharmacology ofCannabis.Nature 228:134–136.Google Scholar
  4. 4.
    Dewey, W. L., L. S. Harris, andJ. S. Kennedy. 1972. Some pharmacological and toxico-logical effects of 1-trans8-and 1-trans-δ9-THC in laboratory rodents.Arch. Int. Pharmacodyn. 196:133–145.Google Scholar
  5. 5.
    Chesher, G. B., C. J. Dahl, M. Everinoham, D. M. Jackson, H. Marchant-Williams, andG. A. Starmer. 1973. The effect of cannabinoids on intestinal mobility and their antinociceptive effect in mice.Br.J. Pharmacol. 49:588–594.Google Scholar
  6. 6.
    Buxbaum, D., E. Sanders-Bush, andD. H. Efron. 1969. Analgesic activity of tetrahydro-cannabinol in the rat and mouse.Fed. Proc. 28:735.Google Scholar
  7. 7.
    Sanders, J., D. M. Jackson, andG. A. Starmer. 1979. Interactions among the cannabinoids in the antagonism of abdominal constriction response in the mouse.Psychopharmacology 61:281–285.Google Scholar
  8. 8.
    White, H. L., andR. L. Tansik. 1980. Effects of δ9-THC and cannabidiol on phospholipase and other enzymes regulating aracidonate metabolism.Prostaglandins Med. 4:409–411.Google Scholar
  9. 9.
    Burstein, S., andS. A. Hunter. 1978. Prostaglandins andCannabis VI. Release of arachidonic acid from HeLa cells by δ1-THC and other cannabinoids.Biochem. Pharmacol. 27:1275–1280.Google Scholar
  10. 10.
    Burstein, S. andA. Raz. 1972. Inhibition of prostaglandin E2 biosynthesis by δ1-tetrahydro-cannabinol.Prostaglandins 2:369.Google Scholar
  11. 11.
    Burstein, S., E. Levine, andC. Varanelli. 1973. Prostaglandins andCannabis II. Inhibition of biosynthesis by the naturally occurring cannabinoids.Biochem. Pharmacol. 22:2905–2910.Google Scholar
  12. 12.
    Barrett, M. L., D. Gordon, andF. J. Evans. 1985. Isolation fromCannabis sativa L of cannflavin: A novel inhibitor of prostaglandin production.Biochem. Pharmacol. 34:2019–2024.Google Scholar
  13. 13.
    Evans, A. T., E. A. Formukong, andF. J. Evans. 1987. Activation of phospholipase A2 by cannabinoids. Lack of correlation with CNS effects.FEBS Lett. 211:119–122.Google Scholar
  14. 14.
    Evans, A. T., E. A. Formukong, F. J. Evans. 1987. Actions ofCannabis constitutents on enzymes of prostaglandin synthesis: Antiinfiammatory potential.Biochem. Pharmacol. 36:2035–2037.Google Scholar
  15. 15.
    Parkes, M. W., andJ. T. Pickens. 1965. Conditions influencing the inhibition of analgesic drugs of the response to intraperitoneal injections of phenylbenzoquine in mice.Br. J. Pharmacol. 25:81–87.Google Scholar
  16. 16.
    Siegmund, E. A., R. A. Cadmus, andG. Lu. 1957. A method for evaluating both nonnarcotic and narcotic analgesics.Proc. Soc. Exp. Biol. 95:729–731.Google Scholar
  17. 17.
    Hendershot, L. C., andJ. Forsaith. 1959. Antagonism of the frequency of phenylbenzoquinone induced writhing in the mouse by weak analgesics and nonanalgesics.J. Pharmacol. Exp. Ther. 125:237–240.Google Scholar
  18. 18.
    Kinghorn, A. D., andF. J. Evans. 1975. A biological screen of selected species of the genusEuphorbia for skin irritant effects.Planta Med. 28:325.Google Scholar
  19. 19.
    Williamson, E. M., andF. J. Evans. 1981. Inhibition of erythema induced by proinflammatory esters of 12-deoxyphorbol.Acta Pharmacol. Toxicol. 481:47–52.Google Scholar
  20. 20.
    Williamson, E. M., J. Westwick, V. V. Kakkar, andF. J. Evans. 1981. Studies on the mechanism of action of 12-DOPP, a potent platelet aggregating phorbol ester.Biochem. Pharmacol. 30:2691–2696.Google Scholar
  21. 21.
    Collier, H. O. J., L. C. Dineen, C. A. Johnson, andC. Schneider. 1968. Abdominal constriction response and its suppression by analgesic drugs in the mouse.Br. J. Pharmacol. Chemother. 32:295–310.Google Scholar
  22. 23.
    Marks, P., G. Furstenberger, andE. Kownatzki. 1981. Prostaglandin E-mediated mitogenic stimulation of mouse epidermis in vivo by divalent cation ionophore A23187 and by tumor promoter 12-O-tetradecanoyl phorbol-13-acetate.Cancer Res. 41:696–702.Google Scholar
  23. 24.
    Humes, J. L., S. Sadowski, M. Galavage, M. Goldenberg, E. Subers, R. J. Bonney, andF. A. Kuehl. 1982. Evidence for two sources of arachidonic acid for oxidative metabolism by mouse peritoneal macrophages.J. Biol. Chem. 257:1291–1594.Google Scholar
  24. 25.
    Edwards, M. C., andF. J. Evans. 1987. Activity correlations in the phorbol ester series.Bot. J. Linn. Soc. 94:231–246.Google Scholar
  25. 26.
    Calson, R. P., L. O'neill-David, J. Chary, andA. J. Lewis. 1985. Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmaoclogical agents.Agents Actions 17:197–204.Google Scholar
  26. 27.
    Formukong, E. A., A. T.Evans, F. J.Evans. 1987. Inhibition of the cataleptic effect of δ1-tetrahydrocannabinol by noncateleptic constituents ofCannabis sativa L.J. Pharm. Pharmacol. (in press).Google Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • E. A. Formukong
    • 1
  • A. T. Evans
    • 1
  • F. J. Evans
    • 1
  1. 1.Department of Pharmacognosy, The School of PharmacyUniversity of LondonLondonEngland

Personalised recommendations